Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMLI and Cyclophosphamide in AML
NCT03467386Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Mar 2018
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclophosphamide in acute myeloid leukemia (AML), sponsored by City of Hope. Primary endpoint: Incidence of adverse events at 24 months. Started Mar 2018; status: active, not recruiting.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03467386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467386.